I found this comment particularly interesting:
Post# of 148112
(Total Views: 592)
Posted On: 02/07/2023 6:59:58 AM
I found this comment particularly interesting:
"The NASH and oncology data sets form the basis of our forward-looking strategy for how CytoDyn will continue to pursue the molecule. We are also developing a longer-acting version of leronlimab with our partners at Oregon Health & Science University. It has been tested in animal models, including rhesus monkeys, and has been shown to remain active inside the body for up to 180 days; treated monkeys are highly resistant to HIV infection, even after repeat challenges on a weekly basis for months. These data are really exciting, and there is no reason this long-acting version cannot also be used for the treatment of solid tumors and NASH.
CytoDyn will continue developing both the short- and long-acting versions of leronlimab. The goal is to bundle these two molecules together and find a strategic partner that can help us advance to later-stage clinical development and commercialization."
"The NASH and oncology data sets form the basis of our forward-looking strategy for how CytoDyn will continue to pursue the molecule. We are also developing a longer-acting version of leronlimab with our partners at Oregon Health & Science University. It has been tested in animal models, including rhesus monkeys, and has been shown to remain active inside the body for up to 180 days; treated monkeys are highly resistant to HIV infection, even after repeat challenges on a weekly basis for months. These data are really exciting, and there is no reason this long-acting version cannot also be used for the treatment of solid tumors and NASH.
CytoDyn will continue developing both the short- and long-acting versions of leronlimab. The goal is to bundle these two molecules together and find a strategic partner that can help us advance to later-stage clinical development and commercialization."
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.
Scroll down for more posts ▼